Quality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation

Sophie Scherer-Trame1,2, Lina Jansen3,4, Lena Koch-Gallenkamp3,5, Volker Arndt4,5, Jenny Chang-Claude6, Michael Hoffmeister3, Hermann Brenner1,3,7

Received: 22 July 2021 / Accepted: 18 November 2021 / Published online: 7 December 2021
© The Author(s) 2021

Abstract
Purpose In Germany, almost every other colorectal cancer (CRC) patient undergoes inpatient cancer rehabilitation (ICR), but research on long-term outcomes is sparse. We aimed to assess health-related quality of life (HRQOL), distress, and posttraumatic growth among former rehabilitants and non-rehabilitants as well as respective differences and to estimate disease-related quality of life deficits in both groups.

Methods HRQOL (EORTC-QLQ-C30/CR29), distress (QSC-R10), and posttraumatic growth (PTGI) were assessed according to past ICR in patients 5-year post-CRC-diagnosis in the German DACHS study. Least square mean differences in HRQOL scores and elevated distress levels (QSC-R10 > 14 points) by ICR were estimated by confounder-adjusted linear and logistic regression, respectively. Differences in PTGI scales were tested for statistical significance. EORTC-QLQ-C30 reference scores from population controls were accessed from the LinDE study to estimate disease-related deficits in both treatment groups.

Results 49% of the included 1906 CRC survivors had undergone ICR. Rehabilitants reported lower HRQOL scores than non-rehabilitants in several dimensions of the EORTC-QLQ-C30/CR29. Differences were pronounced among younger survivors (< 70 years). In younger survivors, past ICR also predicted elevated distress. However, rehabilitants showed higher posttraumatic growth. When compared to 934 population controls, non-rehabilitants and older rehabilitants reported HRQOL scores (EORTC-QLQ-C30) similar to controls except higher levels of bowel dysfunctions, whereas younger rehabilitants experienced deficits regarding most scales (13/15).

Conclusion Our findings suggest a high disease burden 5 years after diagnosis in particular among younger CRC survivors who had undergone ICR. Observed HRQOL deficits are possibly linked to the initial indication for ICR and rehabilitants may benefit from effective follow-up concepts after ICR.

Keywords Inpatient rehabilitation · Colorectal cancer · Cancer survivorship · Health-related quality of life · Distress · Posttraumatic growth
Introduction

Colorectal cancer (CRC) is among the most common cancers globally with approximately 1.9 million new cases in 2020 (Sung et al. 2021). Due to population growth and demographic aging, numbers of new cases are expected to increase to more than 2.4 million by 2035 (Douaihy et al. 2017). Prognosis has improved during the last decades in many Western countries (Allemani et al. 2018; Brenner et al. 2012). Consequently, the implementation of cancer rehabilitation and survivorship care has gained importance. CRC survivors have been found to experience poorer health-related quality of life (HRQOL) than the general population, involving bowel disorders, hampered social participation, and financial problems (Arndt et al. 2017; Caravati-Jouvenceaux et al. 2011; Jansen et al. 2011a, b; Thong et al. 2019). Moreover, the disease and its consequences can affect CRC survivors’ mental wellbeing profoundly (Custers et al. 2016; Jansen et al. 2011a). About every third cancer survivor seems to experience cancer-related psychosocial distress in daily life after treatment period (Herschbach et al. 2020). Nevertheless, coping with the potential life-threatening cancer disease and its consequences may also lead to positive psychological changes regarding interpersonal orientation, life perspective, and self-perception known as posttraumatic growth (Ochoa Arnedo et al. 2019; Salsman et al. 2009; Tedeschi and Calhoun 1996).

In Germany, cancer rehabilitation is predominately offered as multi-professional inpatient programs in specialized rehabilitation clinics, which provide post-acute care directly after primary cancer treatment as well as follow-up care mainly within the first year after completion of treatment. Rehabilitation programs usually last 3 weeks, and consist of closely coordinated interventions such as nutrition counseling, physical and exercise therapy and stoma care, patient education, and psychological support. In addition to the reduction of physical disabilities, rehabilitation programs aim to impart knowledge about the disease and sociomedical aspects and to teach self-management strategies to cope with the disease and disabilities in daily life (Bilsing et al. 2015).

According to the German CRC S3-Guideline, all CRC patients with sufficient capacity to tolerate rehabilitation treatment should receive an offer for cancer rehabilitation (German Guideline Program in Oncology 2019). In addition to capacity, preconditions set by healthcare payers include patients’ need for rehabilitation, e.g., cancer or therapy-related physical or mental impairments interfering with daily life, professional or social life, and a positive rehabilitation prognosis. Results from a patient survey indicate that applications for cancer rehabilitation at the respective payers are usually successful (Deck et al. 2019). The German Pension Insurance acts as a major healthcare payer for cancer rehabilitation. In contrast to non-cancer-specific indications, it funds rehabilitation measures not only for working but also for a large proportion of retired patients next to statutory health insurances. About 44–50% of the CRC patients undergo inpatient cancer rehabilitation (ICR) (Deck et al. 2019; Nowossadeck and Barnes 2016; Scherer-Traine et al. 2021; Waldmann et al. 2007). Reasons for non-utilization of ICR include no perceived disability, family ties, job commitments, and the wish to return to daily life (Deck et al. 2019).

Despite the high utilization of ICR among CRC patients, evidence of effectiveness of such treatment is limited (Scherer et al. 2021). Previous studies have observed improvements in several dimensions of HRQOL suggesting largest benefits with respect to global quality of life, physical, emotional, social functioning, and fatigue (Lamprecht et al. 2017; Riedl et al. 2017; Singer and Schulte 2009). However, these studies were of uncontrolled design (i.e., no inclusion of non-rehabilitants), and it is unknown if the improvements persist over time or wane after ICR as seen for other health-related outcomes (Allgayer et al. 2005, 2012; Biskup et al. 1994; Mehnert et al. 2013). When compared to reference values from the general population, CRC rehabilitants showed deficits in most dimensions of HRQOL before ICR, which may reflect the indication for treatment (Riedl et al. 2017; Singer and Schulte 2009). Due to the short observation periods of the respective studies, little is known about long-term HRQOL deficits in CRC survivors, who had undergone ICR. Moreover, study findings regarding the reduction of psychological distress during or after ICR are inconsistent (Klocker et al. 2018; Lamprecht et al. 2017; Riedl et al. 2017; Ross et al. 2015). Since rehabilitation research mainly focuses on health outcomes among rehabilitants, potential long-term HRQOL deficits in cancer survivors, who have not undergone ICR, are largely unknown.

Thus, we aimed to assess HRQOL, cancer-related distress, and posttraumatic growth among former rehabilitants and non-rehabilitants 5 years after CRC diagnosis, and to estimate respective differences between both treatment groups. We furthermore aimed to assess HRQOL deficits among former rehabilitants and non-rehabilitants in comparison with population controls.

Materials and methods

Study design and population

Our analysis is based on CRC patients recruited in the DACHS (Darmkrebs: Chancen der Verhütung durch...
Data collection and follow-up

Trained interviewers obtain sociodemographic data, lifestyle-related information, and the medical history of the participants during a standardized face-to-face interview at baseline close to initial diagnosis. For CRC patients, collected discharge letters and pathology reports provide tumor- and surgery-related information. Three years after diagnosis, therapy-related information including the utilization of ICR (yes/no) and name of rehabilitation clinic is given retrospectively by the attending general practitioners and/or oncologist. The physicians fill out questionnaires based on patient records and provide medical reports. Five years after diagnosis, participants receive a follow-up questionnaire by mail to assess HRQOL and further self-reported outcomes. If participants refuse to fill out the questionnaire but are willing to answer a short version of the questionnaire including only personal and medical information, the short version of the questionnaire is sent out. Throughout the study, patient’s vital status registered by the population registries is checked regularly. For this analysis, an additional retrospective collection of rehabilitation discharge letters via rehabilitation clinics and treating physicians was conducted for a subset of rehabilitants to approximate timing of ICR after CRC diagnosis.

Inclusion and exclusion criteria

For the current analysis, we included CRC patients diagnosed in 2005–2013 who were still alive 5 years after diagnosis and who participated in the 5-year follow-up (5YFU) in 2010–2018. We excluded CRC survivors with unavailable information on utilization of ICR or who underwent outpatient rehabilitation care only from the analysis. We furthermore excluded participants who provided a short version of the follow-up questionnaire only.

Assessment of HRQOL, distress, and posttraumatic growth

HRQOL was measured with the EORTC-QLQ-C30 questionnaire Version 3.0 (Aaronson et al. 1993) at 5YFU. The instrument was developed by the European Organization for Research and Treatment of Cancer and includes one global quality-of-life scale, five functioning scales (physical, cognitive, role, emotional, and social), and nine symptom scales (insomnia, fatigue, pain, dyspnea, constipation, diarrhea, appetite loss, nausea and vomiting, and financial impact). Participants were asked to rate each item on a Likert scale from 1 (“not at all”) to 4 (“very high”). Scores for every scale were calculated and linearly transformed to a 0–100 scale according to the scoring manual (Fayers et al. 2001). Higher scores on the global and functioning scales reflect better HRQOL, whereas higher scores on the symptom scales indicate higher symptom burden.

In addition to the core questionnaire, the CRC-specific submodule (EORTC-QLQ-CR29) was administered to assess 4 CRC-related functioning (future perspective, body image, weight, and sexual interest) and 18 symptom scales (Gujral et al. 2007; Whistance et al. 2009). Scoring and interpretation of scores were analogues to the core questionnaire (Fayers et al. 2001).

Cancer-related distress was measured with the Questionnaire on Stress in Cancer Patients (QSC-R10) (Book et al. 2011). Its ten items address the impact of cancer-related stressors including psychosomatic complaints, fears, information deficits, everyday life restrictions, and social strains. The instrument is regularly used as a screening tool in clinical practice to identify psychosocial supportive needs in cancer patients. Based on the total score, we classified a value above 14 points as a positive screening result (Book et al. 2011) reflecting an elevated level of distress.

Posttraumatic growth was measured with selected scales of the Posttraumatic Growth Inventory (Tedeschi and Calhoun 1996). The instrument assesses positive outcomes as consequences of a traumatic event. The 5YFU included all scale-specific items for the factors: new possibilities, spiritual change, and appreciation of life. Each factor scale ranges from 0 to 5. Higher scores imply stronger posttraumatic growth in the respective area (Tedeschi and Calhoun 1996).

Reference HRQOL scores from the general population

To estimate HRQOL deficits among rehabilitants and non-rehabilitants in comparison to population controls, we included data from the LinDE study. The LinDE study was a cross-sectional survey conducted in 2013/2014 to obtain normative HRQOL data, among other self-reported health outcomes, in a randomly selected sample of the German
population for comparisons with cancer patients and survivors. Age- and sex-based sampling was performed by the regional municipal offices. Potential participants, aged 18 and above, received study information and the questionnaire including the EORTC-QLQ-C30 instrument by mail. In contrast to most published aggregated normative HRQOL data (Nolte et al. 2019; Waldmann et al. 2013), the LinDE study was a nationwide study, oversampling the older age groups to guarantee a sufficient sample size for comparisons with cancer survivors in those age groups most affected by cancer. Moreover, data are available on an individual level. The response rate was 29%. Further study details are published elsewhere (Arndt et al. 2017). Based on the age- and sex-specific distribution of the CRC rehabilitants in the DACHS study, we performed a frequency distribution matching and drew a sample of comparable population controls after excluding controls outside of rehabilitants’ age range or with a prior history of CRC.

Statistical analysis

Patient-reported outcomes according to utilization of ICR among CRC survivors

All patient-reported outcomes were analyzed for younger and older survivors (i.e., age at follow-up < / ≥ 70 years) separately. Adjusted means for all HRQOL scales (EORTC-QLQ-C30 /CR29) were computed using multivariable linear regression models to describe and compare HRQOL among survivors who had undergone ICR (rehabilitants) and those who had not undergone ICR (non-rehabilitants). Models were stratified for age at follow-up, and adjusted for baseline variables including sex, education, partnership, employment status, health insurance type, UICC stage, tumor location, laparoscopic surgery, radiotherapy, chemotherapy, ostomy, comorbidities (Charlson comorbidity index (Charlson et al. 1987)), and prediagnosis physical activity level (categorization of covariates see Table 1). We selected the potential confounders based on a previous analysis of determinants of receiving ICR (Scherer-Trame et al. 2021) and on predictors of HRQOL (Bours et al. 2016). Differences between rehabilitants and non-rehabilitants were quantified by adjusted least square mean differences (LSMD).

We assessed positivity with respect to cancer-related distress among rehabilitants and non-rehabilitants, and compared it by Chi-square test of independence and multivariable logistic regression models, adjusting for the same baseline variables outlined above for the linear regression models.

To assess potential differences between rehabilitants and non-rehabilitants on single posttraumatic growth scales, means and medians by treatment groups were calculated, and Mann–Whitney U test was applied.

Deficits in HRQOL of CRC survivors in comparison to population controls

We estimated HRQOL deficits assessed with the core questionnaire (EORTC-QLQ-C30) among rehabilitants and non-rehabilitants separately in comparison to population controls by linear regression models. Models were stratified by age at follow-up/survey (< / ≥ 70 years) and adjusted for sex and education. Adjusted means for each group (rehabilitants/non-rehabilitants/controls) were computed and deficits were quantified by adjusted LSMD.

All analyses were performed on SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Statistical significance was defined by a two-sided $P < 0.05$.

Results

DACHS study participants

Among the 2125 CRC survivors who participated in the 5YFU (response rate 86.5%), 154 (7.2%) sent back a short form of the questionnaire only, for 63 participants (3.0%) prior ICR was unknown and two participants (<0.1%) underwent outpatient rehabilitation only. In the final analyses, we included 1906 survivors (see Supplementary Fig. S1). Sociodemographic and clinical characteristics of survivors according to past utilization of ICR are presented in Table 1. About 11% of the survivors had experienced CRC recurrence until the 5YFU. The mean age of the participants was 66.3 at diagnosis and 71.3 at follow-up (± 10.4). Approximately half (49%) of the participants had undergone ICR. Rehabilitants were slightly younger and more likely to be employed at the time of diagnosis, to have no partner, to have statutory health insurance, and were less likely to be diagnosed with cancer stage I compared to non-rehabilitants. Based on available rehabilitation discharge letters for a subset of rehabilitants (53%), time from diagnosis to start of ICR was calculated. The majority of rehabilitants underwent ICR within the first 2 months after CRC diagnosis (median = 1.7 months) and the mean time from diagnosis to start of ICR was 5.2 months (standard deviation = 7.4 months).

Patient-reported outcomes among rehabilitants and non-rehabilitants

HRQOL

Table 2 presents adjusted HRQOL mean scores (EORTC-QLQ-C30) for participants below and above 70 years of age by prior utilization of ICR, and shows LSMD between
Table 1  Characteristics of colorectal cancer survivors according to rehabilitation treatment

| Sociodemographic, clinical, and lifestyle characteristics* | Total          | Rehabilitants | Non-rehabilitants | p value** |
|------------------------------------------------------------|----------------|---------------|------------------|----------|
| N=1906 (100%)                                              | n=934 (49.0%)  | n=972 (51.0%) |                  |          |
| N                                          | N     | Col % | n     | Col % | n     | Col % |
| Age at diagnosis (in years)                            |       |       |       |       |       |       |
| < 50                                        | 123   | 6.5   | 73    | 7.8   | 50    | 5.1   | < .0001^a |
| 50–64                                       | 630   | 33.1  | 342   | 36.6  | 288   | 29.6  |          |
| 65–79                                       | 981   | 51.5  | 432   | 46.3  | 549   | 56.5  |          |
| ≥ 80                                        | 172   | 9.0   | 87    | 9.3   | 85    | 8.7   |          |
| Sex                                         |       |       |       |       |       |       | 0.0076^b  |
| Women                                       | 750   | 39.4  | 396   | 42.4  | 354   | 36.4  |          |
| Men                                         | 1156  | 60.7  | 538   | 57.6  | 618   | 63.6  |          |
| Years of school education^1                  |       |       |       |       |       |       | 0.1106^b  |
| ≤ 9                                         | 1186  | 62.4  | 583   | 62.4  | 603   | 62.0  |          |
| 10                                          | 352   | 18.5  | 185   | 19.8  | 167   | 17.2  |          |
| 12/13                                       | 364   | 19.1  | 163   | 17.5  | 201   | 20.7  |          |
| Employment status^1                          |       |       |       |       |       |       |          |
| Employed                                    | 493   | 26.0  | 296   | 31.7  | 197   | 20.3  | < .0001^a |
| Self-employed                                | 56    | 3.0   | 17    | 1.8   | 39    | 4.0   |          |
| Unemployed                                   | 28    | 1.5   | 19    | 2.0   | 9     | 0.9   |          |
| Retired                                     | 1153  | 60.8  | 520   | 55.7  | 633   | 65.1  |          |
| Housewife/-man                              | 168   | 8.9   | 79    | 8.5   | 89    | 9.2   |          |
| Living in a partnership^1                   |       |       |       |       |       |       | 0.0187^b  |
| Yes                                         | 1523  | 80.1  | 725   | 77.6  | 798   | 82.1  |          |
| No                                          | 379   | 19.9  | 206   | 22.1  | 173   | 17.8  |          |
| Health insurance                            |       |       |       |       |       |       |          |
| Statutory                                   | 1356  | 71.1  | 691   | 74.0  | 665   | 68.4  | < .0001^a |
| Private                                     | 188   | 9.9   | 62    | 6.6   | 126   | 13.0  |          |
| Unknown                                     | 362   | 19.0  | 181   | 19.4  | 181   | 18.6  |          |
| Cancer site                                 |       |       |       |       |       |       | 0.7097^b  |
| Colon                                       | 1127  | 59.1  | 557   | 59.6  | 570   | 58.6  |          |
| Rectum                                      | 779   | 40.9  | 377   | 40.4  | 402   | 41.4  |          |
| Tumor stage, UICC^2                         |       |       |       |       |       |       |          |
| I                                           | 534   | 28.4  | 229   | 24.5  | 305   | 31.4  | 0.0076^a  |
| II                                          | 639   | 34.0  | 324   | 34.7  | 315   | 32.4  |          |
| III                                         | 641   | 34.0  | 336   | 36.0  | 305   | 31.4  |          |
| IV                                          | 68    | 3.6   | 36    | 3.9   | 32    | 3.3   |          |
| Tumor resection^1                            |       |       |       |       |       |       |          |
| Non                                         | 3     | 0.2   | 2     | 0.2   | 1     | 0.1   | 0.2433^b  |
| Open                                        | 1582  | 83.1  | 783   | 83.8  | 799   | 82.2  |          |
| Laparoscopic                                 | 318   | 16.7  | 146   | 15.6  | 172   | 17.7  |          |
| Ostomy^1                                     |       |       |       |       |       |       |          |
| Yes                                         | 613   | 32.2  | 320   | 34.3  | 295   | 30.3  | 0.0699^b  |
| No                                          | 1289  | 67.8  | 613   | 65.6  | 676   | 69.5  |          |
| Chemotherapy^1                               |       |       |       |       |       |       | 0.0567^b  |
| Yes                                         | 790   | 41.5  | 408   | 43.7  | 382   | 39.3  |          |
| No                                          | 1115  | 58.5  | 525   | 56.2  | 590   | 60.7  |          |
| Radiation                                   |       |       |       |       |       |       | 0.3471^b  |
| Yes                                         | 356   | 18.7  | 183   | 19.6  | 173   | 17.8  |          |
| No                                          | 1550  | 81.3  | 751   | 80.4  | 799   | 82.2  |          |
Among younger CRC survivors, we observed poorer functioning of former rehabilitants in 4/5 scales (cognitive, role, emotional, and social) and higher symptom burden in 4/9 scales (insomnia, fatigue, pain, and dyspnea), in addition to lower global quality of life 5 years after diagnosis. LSMD between younger rehabilitants and younger non-rehabilitants were mostly of moderate size (< 8 points), but always indicating poorer functioning and higher symptom in rehabilitants. Differences in HRQOL scores according to prior utilization of ICR were less pronounced (< 5 points) in older participants and statistically significant only for the following scales: emotional functioning, cognitive functioning, insomnia, fatigue, nausea and vomiting.

Among older rehabilitants, 42.1% were screened positive for elevated distress levels, whereas 23.4% were screened positive among the non-rehabilitants 5 years after diagnosis ($p < 0.001$, adjusted odds ratio in the logistic regression: aOR 2.46, 95% CI 1.71–3.54). Among older CRC survivors, proportions of positive screened were similar among rehabilitants (30.2%) and non-rehabilitants (26.6%) ($p = 0.187$, aOR 1.19, CI 0.90–1.58).

### Distress

Among the younger rehabilitants, 42.1% were screened positive for elevated distress levels, whereas 23.4% were screened positive among the non-rehabilitants 5 years after diagnosis ($p < 0.001$, adjusted odds ratio in the logistic regression: aOR 2.46, 95% CI 1.71–3.54). Among older CRC survivors, proportions of positive screened were similar among rehabilitants (30.2%) and non-rehabilitants (26.6%) ($p = 0.187$, aOR 1.19, CI 0.90–1.58).

### Posttraumatic growth

Rehabilitants of both age groups reported higher post-traumatic growth in several dimensions compared to non-rehabilitants. Table 4 presents results in detail. For younger survivors, results implied higher symptom burden (up to five points) in rehabilitants regarding the following scales: dry mouth, urinary frequency, urinary incontinence, stool frequency, flatulence, embarrassed by bowel movements, buttock pain, and dyspareunia. LSMD were generally less pronounced in older survivors than in younger survivors.

### Table 1 (continued)

| Sociodemographic, clinical, and lifestyle characteristics* | Total | Rehabilitants | Non-rehabilitants | $p$ value** |
|------------------------------------------------------------|-------|--------------|-------------------|------------|
| **N=1906 (100%)**                                          |       | n=934 (49.0%) | n=972 (51.0%)     |            |
| **N** | Col % | **n** | Col % | **n** | Col % |
| CCI scores3 |       |       |       |       |       |
| 0      | 1185  | 62.2  | 597  | 63.9  | 588  | 60.5  | 0.1543 |
| 1      | 397   | 20.8  | 196  | 21.0  | 201  | 20.7  |       |
| 2      | 188   | 9.9   | 78   | 8.4   | 110  | 11.3  |       |
| 3+     | 136   | 7.1   | 63   | 6.7   | 73   | 7.5   |       |
| Prediagnosis physical activity level1,4 |       |       |       |       |       |
| Low    | 627   | 33.1  | 273  | 29.2  | 354  | 36.4  | 0.004 |
| Medium | 633   | 33.4  | 328  | 35.1  | 305  | 31.4  |       |
| High   | 636   | 33.5  | 327  | 35.0  | 309  | 31.8  |       |
| Recurrence until 5YFU1 |       |       |       |       |       |
| Yes    | 205   | 10.8  | 89   | 9.5   | 116  | 11.9  | 0.1036 |
| No     | 1699  | 89.2  | 844  | 90.4  | 855  | 88.0  |       |

CCI Charlson comorbidity index score; UICC International Union against Cancer; 5YFU 5-year follow-up
*Patient characteristics refer to the time around CRC diagnosis, unless otherwise stated
**P values of the comparison between rehabilitants and non-rehabilitants from Chi-square test of independence (a) or Fisher’s exact test (b)
1–10 missings
24 missings
3The Charlson comorbidity index (CCI) (Charlson et al. 1987) was used to score reported comorbidities and group participants into four groups from no (0) to severe comorbidity (3+)
4Prediagnosis physical activity level was assessed as metabolic equivalents hours per week and categorized by tertiles according to patient-reported type of activity and averages of minutes spent: Low: Q1<88.2; medium: Q2=88.2–153.5; high: Q3 ≥ 153.5 MET hours/week
rehabilitants, significantly higher growth was observed for the dimensions new possibilities and appreciation of life, and for older rehabilitants, significantly higher growth was observed related to new possibilities and spiritual enhancement.

**Deficits in HRQOL of CRC survivors in comparison to population controls**

LinDE study: population controls

From 2849 eligible LinDE participants, we excluded 406 whose age was outside the rehabilitants’ age range at follow-up (39–96 years) and 32 patients with a history of CRC. After the sex- and age-based frequency distribution matching, HRQOL data from 934 population controls remained for further analysis (see Supplementary Fig. S1). The education level of controls was categorized in the same way as for the DACHS participants into ≤ 9 (46.1%), 10 (21.2%), or 12/13 (28.9%) school years. Since controls had completed higher education more often, we adjusted the following analyses for education level. The matching achieved same sex and age-specific distributions in controls as presented in Table 1 for the rehabilitants.

**HRQOL deficits in rehabilitants and non-rehabilitants**

Sex and education-adjusted means of all EORTC-QLQ-C30 scales are presented by age group and compared to population controls in Table 2. Irrespective of age and past ICR, CRC survivors presented higher scores for both digestive-related scales compared to controls. Deficits were smaller for constipation (up to ten points) than for diarrhea (up to 25 points). Moreover, we observed poorer social functioning (by up to 16 points) and higher financial burden (by up to 12 points) in younger survivors of both treatment

| Table 2 HRQOL (EORTC-QLQ-C30 scores) among rehabilitants and non-rehabilitants stratified by age |
|------------------------------------------------|
| **Age at follow-up < 70 years (n = 752)** | **Age at follow-up ≥ 70 years (n = 1154)** |
|------------------------------- |------------------------------- |
| **Rehabilitants** | **Non-rehabilitants** | **Rehabilitants vs non-rehabilitants** | **Rehabilitants** | **Non-rehabilitants** | **Rehabilitants vs non-rehabilitants** |
| Mean (SE)¹ | Mean (SE)¹ | Mean Diff. (95% CI)¹ | Mean (SE)¹ | Mean (SE)¹ | Mean Diff. (95% CI)¹ |
| **Functioning scales**² | | | | | |
| Physical | 79.0 (2.5) | 81.1 (2.4) | − 2.0 (− 4.9, 0.9) | 75.6 (2.8) | 76.9 (2.8) | − 1.3 (− 4.2, 1.6) |
| Role | 68.1 (3.9) | 74.6 (3.6) | − 6.5 (− 10.9, − 2.0) | 71.1 (3.7) | 74.8 (3.6) | − 3.7 (− 7.5, 0.1) |
| Emotional | 67.7 (3.5) | 72.0 (3.3) | − 4.4 (− 8.4, − 0.4) | 71.9 (2.9) | 75.2 (2.9) | − 3.3 (− 6.3, − 0.3) |
| Cognitive | 74.5 (3.0) | 81.8 (2.8) | − 7.3 (− 10.8, − 3.8) | 78.1 (2.8) | 81.4 (2.8) | − 3.3 (− 6.2, − 0.4) |
| Social | 68.6 (4.0) | 76.4 (3.7) | − 7.9 (− 12.4, − 3.3) | 77.3 (3.5) | 79.2 (3.4) | − 1.9 (− 5.5, 1.7) |
| Global QOL | 62.4 (3.0) | 68.8 (2.8) | − 6.4 (− 9.9, − 2.9) | 60.5 (2.6) | 61.8 (2.5) | − 1.3 (− 3.9, 1.4) |
| **Symptom scales**³ | | | | | |
| Insomnia | 38.1 (4.6) | 31.6 (4.3) | 6.5 (1.2, 11.7) | 40.3 (3.8) | 35.4 (3.7) | 4.9 (0.9, 8.8) |
| Fatigue | 37.4 (3.6) | 32.4 (3.4) | 5.1 (0.9, 9.2) | 41.6 (3.1) | 36.8 (3.1) | 4.8 (1.6, 8.0) |
| Pain | 25.8 (3.9) | 19.5 (3.6) | 6.2 (1.8, 10.7) | 28.5 (3.6) | 24.9 (3.5) | 3.6 (− 0.1, 7.3) |
| Dyspnea | 27.4 (3.7) | 25.6 (3.5) | 1.8 (− 2.4, 6.1) | 27.3 (3.8) | 23.9 (3.7) | 3.4 (− 0.4, 7.2) |
| Constipation | 13.0 (3.6) | 7.7 (3.3) | 5.3 (1.2, 9.4) | 12.5 (3.3) | 11.6 (3.2) | 0.8 (− 2.5, 4.2) |
| Diarrhea | 28.3 (4.3) | 25.0 (4.0) | 3.3 (− 1.7, 8.3) | 27.6 (3.4) | 24.8 (3.3) | 2.9 (− 0.6, 6.4) |
| Appetite loss | 12.1 (2.6) | 11.2 (2.4) | 0.9 (− 2.1, 3.9) | 9.6 (2.7) | 6.9 (2.6) | 2.7 (0.0, 5.4) |
| Nausea and vomiting | 8.9 (1.9) | 8.5 (1.8) | 0.4 (− 1.8, 2.6) | 4.9 (1.5) | 3.3 (1.5) | 1.6 (0.0, 3.1) |
| Financial impact | 28.9 (4.2) | 24.5 (3.9) | 4.4 (− 0.4, 9.2) | 13.3 (2.8) | 10.6 (2.8) | 2.7 (− 0.2, 5.6) |

Significant mean differences are printed in bold
CI confidence interval; Diff. differences; SE standard error

¹Adjusted for sex, education, partnership, employment status, type of health insurance, UICC stage, tumor location, laparoscopic surgery, radiotherapy, chemotherapy, ostomy, comorbidities, and pre-diagnosis physical activity. Covariates include baseline information

²Higher scores indicate better functioning/negative differences indicate poorer functioning compared to respective reference group. Missing values for every scale < 1%

³Higher scores indicate higher symptom burden/positive differences indicate higher symptom burden compared to respective reference groups. Missing values for every scale < 1%
groups. However, all deficits were considerably more pronounced in younger rehabilitants. Older rehabilitants and non-rehabilitants of both age groups presented little less pain symptoms and showed comparable HRQOL scores to same-aged controls besides the mentioned deficits. Younger rehabilitants, on the other hand, showed HRQOL deficits in every scale except the dimensions pain and appetite loss.

**Discussion**

Five years after CRC diagnosis, we observed differences in several health-related outcomes between former rehabilitants and non-rehabilitants. Our results indicate higher physical and psychosocial disease burden but also higher posttraumatic growth among rehabilitants. Differences were generally more pronounced among younger than older rehabilitants and non-rehabilitants of both age groups. The observed deficits were more pronounced in younger rehabilitants, possibly due to higher disease burden and lower adaptive capacity in this group. Further research is needed to understand the underlying mechanisms and to develop tailored interventions to support patients during and after rehabilitation.

---

**Table 3** HRQOL (EORTC-QLQ-CR29 scores) among rehabilitants and non-rehabilitants stratified by age

| Functioning scales²  | Mean (SE)¹ | Mean (SE)¹ | Mean Diff. (95% CI)¹ | Mean (SE)¹ | Mean (SE)¹ | Mean Diff. (95% CI)¹ |
|----------------------|------------|------------|----------------------|------------|------------|----------------------|
| Body image³          | 66.3 (3.6) | 74.7 (3.4) | −8.4 (−12.6, −4.2)   | 78.3 (2.8) | 80.1 (2.7) | −1.7 (−4.5, 1.1)     |
| Future perspective³  | 61.4 (4.4) | 64.1 (4.1) | −2.7 (−7.7, 2.3)     | 60.7 (3.9) | 62.8 (3.8) | −2.0 (−6.0, 1.9)     |
| Weight³              | 71.7 (4.4) | 77.4 (4.1) | −5.7 (−10.8, −0.6)   | 78.8 (3.6) | 81.0 (3.5) | −2.2 (−5.9, 1.4)     |
| Sexual interest women³ | 26.1 (7.9) | 27.9 (7.9) | −1.8 (−9.8, 6.1)     | 19.1 (5.7) | 21.2 (5.7) | −2.1 (−7.6, 3.3)     |
| Sexual interest men³ | 54.3 (8.5) | 56.9 (8.0) | −2.6 (−9.3, 4.0)     | 47.3 (5.6) | 46.9 (5.4) | 0.4 (−4.7, 5.5)      |

**Symptom scales³  | Mean (SE)³ | Mean (SE)³ | Mean Diff. (95% CI)³ | Mean (SE)³ | Mean (SE)³ | Mean Diff. (95% CI)³ |
|-------------------|------------|------------|----------------------|------------|------------|----------------------|
| Dry Mouth³        | 25.1 (3.8) | 22.2 (3.5) | 2.9 (−1.5, 7.3)      | 29.4 (3.6) | 25.3 (3.5) | 4.2 (0.5, 7.8)       |
| Trouble with taste³ | 14.4 (3.3) | 12.3 (3.9) | 2.1 (−1.7, 5.9)      | 12.1 (2.7) | 10.9 (2.6) | 1.1 (−1.6, 3.9)     |
| Hair loss³        | 16.8 (3.1) | 16.7 (2.9) | 0.1 (−3.5, 3.7)      | 14.3 (2.8) | 11.9 (2.7) | 2.3 (−0.5, 5.2)     |
| Urinary frequency³ | 31.9 (3.6) | 32.4 (3.3) | −0.6 (−4.7, 3.6)     | 47.8 (3.2) | 43.5 (3.1) | 4.4 (1.1, 7.6)      |
| Urinary incontinence³ | 10.4 (3.2) | 10.2 (3.0) | 0.2 (−3.5, 3.9)      | 21.6 (3.3) | 15.7 (3.27) | 5.9 (2.5, 9.3)     |
| Dysuria³          | 1.7 (1.7)  | 1.0 (1.6)  | 0.6 (−1.3, 2.6)      | 4.0 (1.8)  | 2.9 (1.7)  | 1.1 (−0.7, 2.9)     |
| Stool frequency³  | 37.6 (3.6) | 32.6 (3.4) | 4.9 (0.8, 9.1)       | 34.6 (2.9) | 31.2 (2.8) | 3.3 (0.4, 6.2)      |
| Fecal incontinence³ | 27.3 (3.6) | 22.9 (3.3) | 4.4 (0.3, 8.5)       | 26.0 (3.0) | 23.4 (3.0) | 2.6 (−0.5, 5.6)     |
| Blood/mucus in stool³ | 5.9 (1.6)  | 4.5 (1.5)  | 1.4 (−0.5, 3.2)      | 4.0 (1.2)  | 3.5 (1.2)  | 0.4 (−0.8, 1.6)     |
| Sore skin³        | 22.6 (3.8) | 17.3 (3.6) | 5.3 (0.9, 9.7)       | 25.0 (3.0) | 22.4 (3.0) | 2.6 (−0.5, 5.7)     |
| Stoma care problems³ | 26.5 (11.4) | 23.9 (11.4) | 2.6 (−9.5, 14.7)     | 13.8 (16.5) | 15.1 (16.0) | 12.4 (−19.2, 26.6) |
| Bloating³         | 35.5 (4.3) | 25.7 (4.1) | 9.8 (4.8, 14.8)      | 26.1 (3.5) | 22.9 (3.4) | 3.2 (−0.3, 6.8)     |
| Flatulence³       | 41.0 (4.3) | 31.2 (4.0) | 9.8 (4.8, 14.8)      | 40.8 (3.7) | 35.1 (3.6) | 5.8 (2.1, 9.5)      |
| Embarrassment³    | 29.2 (4.2) | 21.1 (3.9) | 8.2 (3.4, 13.0)      | 23.5 (3.4) | 19.7 (3.3) | 3.7 (0.3, 7.2)      |
| Abdominal pain³   | 17.9 (3.4) | 10.9 (3.2) | 7.1 (3.2, 10.9)      | 13.8 (2.6) | 11.7 (2.6) | 2.2 (−0.5, 4.9)     |
| Buttock pain³     | 16.6 (3.5) | 12.2 (3.3) | 4.4 (0.4, 8.4)       | 22.1 (2.7) | 19.0 (2.7) | 3.1 (0.3, 5.9)      |
| Impotence³        | 50.1 (9.9) | 47.3 (9.3) | 2.8 (−5.0, 10.5)     | 61.1 (6.7) | 64.8 (6.6) | −3.7 (−10.0, 2.6)   |
| Dyspareunia³      | 28.9 (9.4) | 21.7 (9.5) | 7.3 (−2.7, 17.2)     | 2.9 (5.2)  | −2.5 (5.3) | 5.4 (0.3, 10.5)     |

Significant mean differences are printed in bold

CI confidence interval; Diff. differences; SE standard error

¹Adjusted for sex (excluding sex-specific scales), education, partnership, employment status, type of health insurance, UICC stage, tumor location, laparoscopic surgery, radiotherapy, chemotherapy, ostomy (excluding stoma care scale), comorbidities, and pre-diagnosis physical activity. Covariates include baseline information

²Higher scores indicate better functioning/negative differences indicate poorer functioning compared to respective reference group
³Higher scores indicate higher symptom burden/positive differences indicate higher symptom burden compared to respective reference groups

<1.2% missing values within the study cohort

unknown/not applicable 3.0% in men, 18.8% in women
<2.5% missing values within the study cohort
unknown/not applicable 6.3% in men, 36.7% in women
Among older CRC survivors. In younger survivors, past ICR was also associated with distress. When compared to population controls, younger survivors of both treatment groups reported deficits with respect to social functioning and financial impact. Irrespective of age and treatment groups, survivors experienced higher levels of bowel dysfunctions. Apart from these deficits, non-rehabilitants and older rehabilitants showed HRQOL scores comparable to population controls, whereas younger rehabilitants experienced deficits in almost every HRQOL dimension.

At first glance, lower levels of HRQOL and higher levels of distress among rehabilitants in comparison to non-rehabilitants may appear surprising, since a previous analysis from the DACHS study had suggested higher survival rates of patients who had undergone ICR (Scherer-Trame et al. 2021). Furthermore, previous, albeit much smaller studies had reported increases in HRQOL of CRC patients during ICR (Lamprecht et al. 2017; Riedl et al. 2017; Singer and Schulte 2009), even though positive changes in health-related outcomes generally seemed to wane over time (Allgayer et al. 2005, 2012; Biskup et al. 1994; Mehnert et al. 2013). However, respective studies also lacked a control group not undergoing ICR, and study results on treatment benefits on psychological distress are not conclusive (Klocker et al. 2018; Lamprecht et al. 2017; Riedl et al. 2017; Ross et al. 2015). Given the cross-sectional assessment of the patient-reported outcomes in our study, the analysis does not allow to draw any conclusions on potential changes in health-related outcomes generally seemed to wane over time. Poorer health outcomes including general health problems, wellbeing, participation, and vitality among CRC survivors who had undergone ICR have been reported previously by Deck et al. (2019). Respective differences between rehabilitants and non-rehabilitants, however, were unadjusted and based on a small sample. Although the aforementioned factors prohibit drawing firm conclusions, the patterns we observed may give rise to a number of hypotheses that might be worth to be followed up.

### Table 4 Posttraumatic Growth Inventory scores among rehabilitants and non-rehabilitants stratified by age

| Posttraumatic Growth Inventory | Age at follow-up < 70 years (n = 752) | Age at follow-up ≥ 70 years (n = 1154) |
|------------------------------|----------------------------------------|----------------------------------------|
|                              | Rehabilitants vs non-rehabilitants | Rehabilitants vs non-rehabilitants |
|                              | Mean (SD) | Median | Mean (SD) | Median | p value | Effect size |
| New possibilities (0–5)       | 2.0 (1.1) | 1.8 | 1.6 (1.1) | 1.6 | < .0001 | − 0.16 |
| Spiritual enhancement (0–5)   | 1.4 (1.4) | 1.0 | 1.3 (1.4) | 1.0 | 0.0877 | − 0.06 |
| Appreciation (0–5)            | 3.2 (1.2) | 3.3 | 2.8 (1.3) | 3.0 | 0.0001 | − 0.14 |
| New possibilities (0–5)       | 1.6 (1.1) | 1.4 | 1.4 (1.1) | 1.2 | 0.0011 | 0.10 |
| Spiritual enhancement (0–5)   | 1.6 (1.4) | 1.5 | 1.4 (1.4) | 1.0 | 0.0073 | 0.08 |
| Appreciation (0–5)            | 2.8 (1.2) | 3.0 | 2.6 (1.4) | 2.7 | 0.0829 | 0.05 |

SD standard deviation;

1 Effect size estimated by Pearson correlation coefficient r

2 Full questionnaire was not administered. Presented single scales (missing values < 2.7% within the study cohort) included all scale-specific items.
up in future research. One such hypothesis would be that rehabilitants might be more health conscious and more alert with respect to detriments in HRQOL or symptoms, and such conscious perception might even be strengthened during ICR. Another hypothesis along similar lines of reasoning might be that ICR may support the development of posttraumatic growth, taking into account that a salutogenetic consciousness, the conveyance of which is a principle of rehabilitation care, and promotes self-care and constructive coping with the disease (Ochoa Arnedo et al. 2019). In addition, higher perceived burden of CRC diagnosis, which was shown to be related to posttraumatic growth (Jansen et al. 2011b), might have led to the decision of undergoing ICR. Nevertheless, for the time being, such hypotheses remain speculative. The final answer on potential effects of ICR on long-term patient-reported outcomes of CRC patients would have to come from randomized controlled trials (RCTs). Although a few mostly small controlled trials have evaluated short-term effects of different treatment modalities among rehabilitants (Allgayer et al. 2004, 2008), to our knowledge, no RCT to date on an intervention comparable to the multidimensional rehabilitation programs offered in Germany has compared long-term outcomes of rehabilitants and non-rehabilitants.

### Deficits in HRQOL in comparison to population controls

The HRQOL deficits we observed in this cohort of CRC were consistent with previous findings from other studies (Arndt et al. 2017; Caravati-Jouvenceaux et al. 2011; Jansen et al. 2011a; Thong et al. 2019). CRC survivors of both treatment and age groups reported higher levels of bowel dysfunctions and younger survivors generally experienced detriments in social participation and higher financial strain. Contrary, the lower pain levels we observed among this cohort of survivors are in line with findings by Thong et al. (2019) and might be explained by a response shift that reflects a general higher threshold of pain perception and tolerance following cancer treatment (Visser et al. 2013). However, in addition to the confirmation of previous results, we were able to identify a group of CRC survivors—younger

| Table 5 Differences in HRQOL (EORTC-QLQ-C30 scores) between CRC survivors and population controls stratified by age |
|---------------------------------------------------------------|
| **Function scales**                                           |
| Mean Diff. (95% CI)                                           |
| Physical                                                      |
| − 4.7 (− 7.6, − 1.9)                                          |
| − 2.1 (− 5.1, 0.9)                                            |
| − 1.5 (− 5.1, 2.0)                                            |
| − 0.1 (− 3.3, 3.5)                                            |
| Role                                                          |
| − 9.7 (− 14.1, − 5.3)                                         |
| − 1.7 (− 6.3, 3.0)                                            |
| − 2.5 (− 7.0, 2.1)                                            |
| 1.8 (− 2.6, 6.2)                                              |
| Emotional                                                     |
| − 4.8 (− 8.7, − 0.8)                                          |
| 0.5 (− 3.7, 4.6)                                              |
| − 4.1 (− 7.5, − 0.7)                                          |
| − 0.7 (− 4.0, 2.6)                                            |
| Cognitive                                                     |
| − 6.4 (− 9.8, − 3.0)                                          |
| 1.8 (− 1.8, 5.4)                                              |
| − 2.5 (− 5.9, 1.0)                                            |
| 1.1 (− 2.2, 4.3)                                              |
| Social                                                        |
| − 16.5 (− 21.0, − 12.0)                                       |
| − 7.2 (− 11.9, − 2.4)                                         |
| − 3.1 (− 7.4, 1.2)                                            |
| − 1.1 (− 5.2, 3.0)                                            |
| Global QOL                                                    |
| − 4.1 (− 7.6, − 0.6)                                          |
| 2.3 (− 1.4, 6.0)                                              |
| 0.1 (− 3.1, 3.3)                                              |
| 1.8 (− 1.2, 4.8)                                              |
| **Symptom scales**                                            |
| Mean Diff. (95% CI)                                            |
| Insomnia                                                      |
| 6.6 (1.5, 11.7)                                               |
| − 0.9 (− 6.3, 4.4)                                            |
| 4.0 (− 0.5, 8.6)                                              |
| − 1.0 (− 5.3, 3.4)                                            |
| Fatigue                                                       |
| 5.7 (1.5, 9.8)                                                |
| − 0.6 (− 4.9, 3.8)                                            |
| 2.9 (− 0.9, 6.8)                                              |
| − 2.2 (− 5.9, 1.5)                                            |
| Pain                                                          |
| − 0.3 (− 4.8, 4.2)                                            |
| − 7.2 (− 11.9, − 2.4)                                         |
| − 7.2 (− 11.5, − 2.8)                                         |
| − 10.9 (− 15.1, − 6.7)                                        |
| Dyspnea                                                       |
| 4.5 (0.3, 8.7)                                                |
| 1.9 (− 2.6, 6.3)                                              |
| 3.5 (− 1.0, 8.0)                                              |
| − 0.5 (− 4.8, 3.9)                                            |
| Constipation                                                  |
| 10.0 (6.3, 13.8)                                              |
| 4.1 (0.2, 8.0)                                                |
| 6.4 (2.6, 10.2)                                               |
| 5.4 (1.7, 9.0)                                                |
| Diarrhea                                                      |
| 25.2 (20.8, 29.5)                                             |
| 19.6 (15.0, 24.1)                                             |
| 15.2 (11.4, 18.9)                                             |
| 11.9 (8.4, 15.5)                                              |
| Appetite loss                                                 |
| 1.5 (− 1.5, 4.4)                                              |
| 0.1 (− 3.0, 3.2)                                              |
| 2.2 (− 1.0, 5.4)                                              |
| − 0.7 (− 3.8, 2.4)                                            |
| Nausea and vomiting                                           |
| 2.1 (0.1, 4.2)                                                |
| 1.4 (− 0.7, 3.6)                                              |
| 1.2 (− 0.8, 2.9)                                              |
| − 0.5 (− 2.2, 1.3)                                            |
| Financial impact                                              |
| 12.5 (7.9, 17.1)                                              |
| 6.1 (1.3, 10.9)                                               |
| 1.9 (− 1.5, 5.3)                                              |
| − 0.7 (− 4.0, 2.6)                                            |

Significant mean differences are printed in bold.

CI confidence interval; CRC colorectal cancer

1Higher scores indicate better functioning/negative differences indicate poorer functioning compared to population controls. Missing values for every scale < 1% within both studies.

2Higher scores indicate higher symptom burden/positive differences indicate higher symptom burden compared to population controls. Missing values for every scale < 1% within both studies.
rehabilitants—who seem to experience deficits in almost every dimension, whereas non-rehabilitants and older rehabilitants showed HRQOL scores comparable to population controls apart from the aforementioned scales. Since employed patients were more likely to receive ICR than retired patients (Scherer-Trame et al. 2021), poorer cognitive, role functioning, and larger financial strain in younger rehabilitants could derive from an unsuccessful return to work as described in breast cancer patients (Schmidt et al. 2019). Larger deficits in social participation might be linked to higher level of digestive dysfunctions as we have found a significant moderate negative correlation between the scales social functioning and diarrhea for both treatment groups ($r = -0.30/-0.33$). Gas and stool leakages and the need for a restroom within reach can affect mobility and social participation severely (Rothbarth et al. 2001). Deficits with respect to emotional and cognitive functioning as well as higher levels of fatigue and insomnia suggest a symptom cluster that indicates higher psychological strain among younger CRC survivors that had undergone ICR.

Younger CRC patients who had undergone ICR may benefit from follow-up concepts after ICR. Follow-up programs aim to maintain treatment success, promote the return to work, and support the rehabilitants applying recommendations into daily life (German Pension Insurance 2019; Koch and Bergelt 2019). However, uptake of these programs is rather low in cancer rehabilitants compared to other indication groups. In recent years, the implementation of telephone- or web-based follow-up concepts has been discussed and tested as pilot projects, since this approach could potentially facilitate nationwide access as well as cost-effective and indication-specific care (Sewöster et al. 2014; Zwerenz et al. 2017).

**Strengths and limitations of the study**

We were able to assess differences with respect to past ICR in a large representative cohort of survivors 5 years after CRC diagnosis. Major strengths of the study include comprehensive confounder adjustment, satisfying completeness of data and the high response rate among the DACHS follow-up participants. Non-responders did not differ regarding sex or cancer stage, but were found to be older, lower educated and to have a higher comorbidity score. However, differences seemed to be minor, and ICR utilization was similar among non-responders (44%) and responders (49%). Valid information on possible repeated ICR stays and on ICR that was administered 3 years after diagnosis was not available. Thus, findings refer to any ICR within the postulated period. Standardized cancer-specific instruments were administered to measure HRQOL and distress, but the cross-sectional assessment did not allow us to draw any conclusions on effectiveness of treatment. Longitudinal assessment of the outcomes and relevant information on medical indication for ICR would be prerequisites to evaluate effectiveness.

We identified HRQOL deficits in rehabilitants and non-rehabilitants in comparison to the general population. In addition to the confirmation of previous findings concerning deficits in CRC survivors, we were able to point out the disease-related health burden in younger survivors who had undergone ICR. The response rate within the LinDE study was low which is common for population-based surveys. Therefore, the possibility has to be kept in mind that healthier individuals were more likely to participate. Since this also might be true for the recruitment of the DACHS study or the participation in the follow-up, observed deficits may still not be overestimated. Education levels were higher among the population controls, but this difference could be adjusted for in the analysis. Despite some limitations, the LinDE study served as a very useful population-based reference due to application of the same questionnaire instruments and conduction during the same calendar years.

**Conclusion**

The utilization of ICR predicted worse HRQOL scores in several dimensions and distress but also higher postransformative growth among CRC survivors. Differences by treatment groups were pronounced in survivors, who were younger than 70 years at follow-up. We found younger rehabilitants to experience strongest deficits of functioning and highest symptom burden when compared to age-matched pairs from the general population. Observed long-term deficits possibly reflect the initial indication for past ICR. Future studies of controlled design and longer observation period are essential to investigate long-term effectiveness of rehabilitation treatment. To optimize treatment allocation and content, further research on determinants of therapy success including potential follow-up concepts after ICR is needed.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00432-021-03865-3.

**Acknowledgements** We would like to thank Ute Handte-Daub and Ansgar Brandhorst for their technical assistance. We thank Ruth Elisa Eyl and Melissa Thong for their advice. We are grateful to the study coordinators and interviewers. We furthermore would like to thank the cooperating resident physicians and the below-listed clinics: Chirurgische Universitätsklinik Heidelberg, Klinik am Gesundbrunnen Heilbronn, St. Vincentiuskrankenhaus Speyer, St. Josefkrankenhaus Heidelberg, Chirurgische Universitätsklinik Mannheim, Diakonissenkrankenhaus Speyer, Krankenhaus Salem Heidelberg, Kreiskrankenhaus Schwetzingen, St. Marienkrankenhaus Ludwigsafen, Klinikum Ludwigshafen, Stadtklinik Frankenthal, Diakoniekrankenhaus Mannheim, Kreiskrankenhaus Sinsheim, Klinikum am Plattenwald Bad Friedrichshall, Kreiskrankenhaus Weinheim, Kreiskrankenhaus Eberbach, Kreiskrankenhaus Büchen, Kreiskrankenhaus Mosbach, Endarmzentrum Mannheim, Kreiskrankenhaus Brackenheim.
Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, and CH 1171/1-1) and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B, and 01GL1712).

Data availability Data analyzed for this publication are not publicly available, but will be shared by the corresponding author upon reasonable request from qualified researchers.

Declarations

Conflict of interest The authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. https://doi.org/10.1093/jnci/85.5.365

Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

Allgayer H, Nicolaus S, Schreiber S (2004) Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment. Cancer Detect Prev 28:208–213. https://doi.org/10.1016/j.cdtp.2004.02.001

Allgayer H, Dietrich CF, Rohde W et al (2005) Prospective comparison of short- and long-term effects of pelvic floor exercise/biofeedback training in patients with fecal incontinence after surgery plus irradiation versus surgery alone for colorectal cancer: clinical, functional and endoscopic/endosonographic findings. Scand J Gastroenterol 40:1168–1175. https://doi.org/10.1080/00365520510023477

Allgayer H, Owen RW, Nair J et al (2008) Short-term moderate exercise programs reduce oxidative DNA damage as determined by high-performance liquid chromatography-electrospray ionization-mass spectrometry in patients with colorectal carcinoma following primary treatment. Scand J Gastroenterol 43:971–978. https://doi.org/10.1080/00365520701766111

Allgayer H, Ignee A, Zipse S et al (2012) Endorectal ultrasound and real-time elastography in patients with fecal incontinence following anorectal surgery: a prospective comparison evaluating short- and long-term outcomes in irradiated and non-irradiated patients. Z Gastroenterol 50:1281–1286. https://doi.org/10.1055/s-0032-1313000

Arndt V, Koch-Gallenkamp L, Jansen L et al (2017) Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncol 56:190–197. https://doi.org/10.1080/0284186X.2016.1266089

Bilsing B, Anger B, Meyer F (2015) Onkologische Rehabilitation bei gastrointestinalen Tumorerkrankungen [Medical Rehabilitation in Gastrointestinal Oncology]. Zentralbl Chir 140:382–389. https://doi.org/10.1055/s-0034-1382845

Biskup M, Uhlmann T, Gärtnner, (1994) Veränderungen körperlicher Beschwerden und Belastungen von Tumorpatienten nach stationärer onkologischer Rehabilitation [Changes in physical complaints and stress in tumour patients after inpatient oncological rehabilitation]. Prax Klin Verhaltensmed Rehabilitation 28:219–229 (German)

Book K, Marten-Mittag B, Henrich G et al (2011) Distress screening in oncology-evaluation of the Questionnaire on Distress in Cancer Patients-short form (QSC-R10) in a German sample. Psychooncology 20:287–293. https://doi.org/10.1002/pon.1821

Bours MJ, van der Linden BW, Winkels RM et al (2016) Candidate predictors of health-related quality of life of colorectal cancer survivors: a systematic review. Oncologist 21:433–452. https://doi.org/10.1634/theoncologist.2015-0258

Brenner H, Chang-Claude J, Seiler CM et al (2011) Protection from colorectal cancer after colonscopy: a population-based, case-control study. Ann Intern Med 154:22–30. https://doi.org/10.7326/0003-4819-154-1.201101040-00004

Brenner H, Bouvier AM, Foschi R et al (2012) Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCASE study. Int J Cancer 131:1649–1658. https://doi.org/10.1002/ijic.26192

Caravati-Jouvenceaux A, Launoy G, Klein D et al (2011) Health-related quality of life among long-term survivors of colorectal cancer: a population-based study. Oncologist 16:1626–1636. https://doi.org/10.1634/theoncologist.2011-0036

Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8

Custers JAE, Gielissen MFM, Janssen SHV et al (2016) Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer 24:555–562. https://doi.org/10.1007/s00520-015-2908-4

Deck R, Babaev V, Katalinic A (2019) Gründe für die Nichtnennungsnahmeaufnahme einer onkologischen Rehabilitation. Ergebnisse einer schriftlichen Befragung von Patienten aus onkologischen Versorgungszentren [Reasons for the Non-Utilisation of an Oncological Rehabilitation. Results of a Written Survey with Patients of Oncological Healthcare Centers]. Rehabilitation 58:243–252. https://doi.org/10.1055/a-0642-1411 (German)

Doualher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C (2017) Colorectal cancer—global burden, trends, and geographical variations. J Surg Oncol 115:619–630. https://doi.org/10.1002/jso.24578

Fayers P, Aaronson NK, Bjordal K et al (2001) EORTC QLQ–C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

German Guideline Program in Oncology (2019) S3-Guideline Colorectal Cancer.Long version 2.1, Ed, German Cancer Society, German Cancer Aid, AWMF, AWMF registrationnumber: 021–0070L, http://www.leitlinienprogramm-onkologie.de/leitlinien/ko lor rektale sar-karzinome/. Accessed 15 Oct 15 2021

German Pension Insurance (2019) Rahmenkonzept zur Nachsorge für medizinische Rehabilitation nach § 15 SGB VI der Deutschen Rentenversicherung in der Fasung vom 01.07.2015 [Framework

Springer
concept for aftercare for medical rehabilitation according to § 15 SGB VI of the German Pension Insurance in the version of 15.07.2019. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/konzepte/systemfragen/konzepte/rahmenkonzept_reha_nachsorge.html. Accessed 01 June 2021

Gujral S, Conroy T, Fleissner C et al (2007) Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire. Eur J Cancer 43:1564–1573. https://doi.org/10.1016/j.ejca.2007.04.005

Herschbach P, Britzelmeier I, Dinkel A et al (2020) Distress in cancer patients: who are the main groups at risk? Psychooncology 29:703–710. https://doi.org/10.1002/pon.5321

Hoffmeister M, Jansen L, Rudolph A et al (2015) Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst 107:dvj045. https://doi.org/10.1093/jnci/dvj045

Jansen L, Herrmann A, Stegmaier C et al (2011a) Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol 29:3263–3269. https://doi.org/10.1200/jco.2010.31.4013

Jansen L, Hoffmeister M, Chang-Claude J et al (2011b) Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life. Br J Cancer 105:1158–1165. https://doi.org/10.1038/bjc.2011.335

Klocker J, Klocker-Kaiser U, Pipam W et al (2018) Langzeiterhebung der biopsychosozialen Situation onkologischer Patienten durch 3-wöchige stationäre onkologische Rehabilitation [Long-term improvement of the bio-psycho-social state of cancer patients after 3 weeks of inpatient oncological rehabilitation: a long-term study at the Humanized Zentrum Althofen]. Wien Med Wochenschr 168:350–360. https://doi.org/10.1007/s10354-018-0619-1.

German

Koch U, Bergelt C (2019) Cancer Survivorship—Die Versorgung von Krebsüberlebenden. Rehabilitation 58:150–152. https://doi.org/10.1055/a-0897-2463.

German

Lamprecht J, Thyroff A, Mau W (2017) Health-related quality of life in rehabilitants with different cancer entities. Eur J Cancer Care 26:e12554. https://doi.org/10.1111/ecc.12554

Mehnert A, Koch U, Sundermann C et al (2013) Predictors of fear of recurrence in patients one year after cancer rehabilitation: a prospective study. Acta Oncol 52:1102–1109. https://doi.org/10.3109/0284186X.2013.765063

Nolte S, Liegli G, Petersen MA et al (2019) General population normative data for the EORTC QLC-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States. Eur J Cancer 107:153–163. https://doi.org/10.1016/j.ejca.2018.11.024

Nowossadeck E, Barnes B (2016) Inanspruchnahme der onkologischen Rehabilitation im Verhältnis zur Krebsinzidenz. [Utilization of oncological rehabilitation in relation to cancer incidence]. Gesundheitswesen 78:A163. https://doi.org/10.1055/s-0036-1586673

Ochoa Arnedo C, Sánchez N, Sumallà EC et al (2019) Stress and growth in cancer: mechanisms and psychotherapeutic interventions to facilitate a constructive balance. Front Psychol 10:177. https://doi.org/10.3389/fpsyg.2019.00177

Riedl D, Giesinger JM, Wüntner LM et al (2017) Improvement of quality of life and psychological distress after inpatient cancer rehabilitation: results of a longitudinal observational study. Wien Klin Wochenschr 129:692–701. https://doi.org/10.1007/s00508-017-1266-z

Ross L, Rottmann N, Andersen KK et al (2015) Distress after a psychosocial cancer rehabilitation course. Main effects and effect modification in a randomised trial at 12 months of follow-up. Acta Oncol 54:735–742. https://doi.org/10.3109/0284186X.2014.998278

Rothbarth J, Bemelman WA, Meijerink WJ et al (2001) What is the impact of fecal incontinence on quality of life? Dis Colon Rectum 44:67–71. https://doi.org/10.1016/BF02234823

Salsman JM, Segerstrom SC, Brechting EH et al (2009) Posttraumatic growth and PTSD symptomatology among colorectal cancer survivors: a 3-month longitudinal examination of cognitive processing. Psychooncology 18:30–41. https://doi.org/10.1002/pon.1367

Scherer S, Jansen L, Boakye D et al (2021) Changes in health-related outcomes among colorectal cancer patients undergoing inpatient rehabilitation therapy: a systematic review of observational and interventional studies. Acta ONcol 60:124–134. https://doi.org/10.1080/0284186X.2020.1828620

Scherer-Tramke S, Jansen L, Arndt V et al (2011) Inpatient rehabilitation therapy among colorectal cancer patients—utilization and association with prognosis: a cohort study. Acta Oncol. https://doi.org/10.1080/0284186X.2011.940274

Schmidt ME, Scherer S, Wiskemann J et al (2019) Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care 28:e13051. https://doi.org/10.1111/ecc.13051

Sewöster D, Haaf H, Märthin S (2014) Telefonische Nachsorge in der medizinischen Rehabilitation—Eine Literaturübersicht [Telefon-based aftercare in medical rehabilitation—A literature review]. Gesundheitswesen 76:A177. https://doi.org/10.1055/s-0034-1387027.

German

Singer S, Schulte T (2009) Lebensqualität von älteren Tumorpatienten. Bedarf an und Nutzen von Anschlussheilbehandlungen [Quality of life in elderly cancer patients—need for and benefit of inpatient rehabilitation]. Dtsch Med Wochenschr 134:121–126. https://doi.org/10.1055/s-0028-1123968.

German

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Tedeschi RG, Calhoun LG (1996) The Posttraumatic Growth Inventory: measuring the positive legacy of trauma. J Trauma Stress 9:455–471. https://doi.org/10.1007/0-387-94368-4

Thong MSY, Koch-Gallenkamp L, Jansen L et al (2019) Age-specific health-related quality of life in long-term and very long-term colorectal cancer survivors versus population controls—a population-based study. Acta Oncol 58:801–810. https://doi.org/10.1080/0284186X.2018.1557340

Visser MR, Oort FJ, Lanschot JJ et al (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangers and Schwartz model. Psychooncology 22:515–522. https://doi.org/10.1002/pon.2114

Waldmann A, Lautz E, Hampe J et al (2007) Poppen-Darmkrebs: Reha-Inanspruchnahme von jüngeren Patienten mit kolorektalem Tumor [Utilization of Inpatient Rehabilitation of Younger Patients with Colorectal Neoplasms—Results of the Project “Poppen-Colorectal Cancer”]. Rehabilitation 46:439–355. https://doi.org/10.1055/s-2007-973828.

German

Waldmann A, Schubert D, Katalinic A (2013) Normative data of the EORTC QLC-C30 for the German population: a population-based survey. PLoS One 8:e71449. https://doi.org/10.1371/journal.pone.0071449

Whistance RN, Conroy T, Chie W et al (2009) Clinical and psychometric validation of the EORTC QLC-C39 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 45:3017–3026. https://doi.org/10.1016/j.ejca.2009.08.014

Journal of Cancer Research and Clinical Oncology (2022) 148:3015–3028

Springer
Zwerenz R, Becker J, Gerzymisch K et al (2017) Evaluation of a trans-diagnostic psychodynamic online intervention to support return to work: A randomized controlled trial. PLOS ONE 12:e0176513. https://doi.org/10.1371/journal.pone.0176513

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.